PRAME and plasma cell myeloma: PRAME is prominently expressed in hematopoietic malignancies as well, with notable prevalence in conditions such as acute myeloid leukemia (AML) (40–60%), acute lymphoblastic leukemia (ALL) (20–40%), myeloma (20–50% of cases), and chronic myeloid leukemia (CML) (30–40%) [32].